Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 472

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 4
Chunk 472
---
 various jurisdictions, including China, Europe and Japan, each of which, if issued, would have an expiration date in 2039.
We also had patents/patent applications directed to the manufacturing process of amdizalisib.
Ranosidenib— The intellectual property portfolio for ranosidenib as of December 31, 2024 is summarized below:
We had a patent family directed to novel small molecule compounds as well as methods of treating cancers with the compounds. In this patent family, we owned patents in various jurisdictions, including China, the United States and Japan, each of which will expire in 2038. We also had patent applications pending in this patent family in various other jurisdictions, including China, the United States, Europe and Japan, each of which, if issued, would have an expiration date in 2038.
HMPL-760—The intellectual property portfolio for HMPL-760 as of December 31, 2024 is summarized below:
We had a patent family directed to novel small molecule compounds as well as methods of treating cancers, inflammatory diseases or auto-immune diseases with such compounds. In this family, we owned patents in the United States, each of which will expire in 2041. We also had patent applications pending in this patent family in various jurisdictions, including China, the United States, Europe and Japan, each of which, if issued, would have an expiration date in 2041. 
​

We also had patent applications directed to the method of preparing intermediates used in the manufacturing process of HMPL-760.
HMPL-295—The intellectual property portfolio for HMPL-295 as of December 31, 2024 is summarized below: 
We had a patent family directed to novel small molecule compounds as well as methods of treating cancers or auto-immune diseases with such compounds. In this patent family, we owned patents in various jurisdictions, including a patent in China, each expiring in 2040. We also had patent applications pending in various jurisdictions, including China, the United States, Europe and Japan, each of which, if issued, would have an expiration date in 2040.
HMPL-653—The intellectual property portfolio for HMPL-653 as of December 31, 2024 is summarized below:
We had a patent family directed to novel small molecule compounds as well as methods of treating cancers, inflammatory diseases or auto-immune diseases with such compounds. In this patent family, we owned patents in various jurisdictions, including one patent in China, exp